Page 41 - TD-1-2

Tumor Discovery Fact & challenges of immunotherapy in TNBC

25. Fan A, Wang B, Wang X, et al., 2021, Immunotherapy regulates obesity-driven breast cancer. Cell Metab., 33(3):
in colorectal cancer: Current achievements and future 499–512.e6.
perspective. Int J Biol Sci., 17(14): 3837–3849.
40. Zhao M, Howard EW, Parris AB, et al., 2017, Alcohol
26. Zhao Q, Yu J, Meng X, 2019, A good start of immunotherapy promotes migration and invasion of triple-negative breast
in esophageal cancer. Cancer Med., 8(10): 4519–4526. cancer cells through activation of p38 MAPK and JNK. Mol
Carcinog., 56(3): 849–862.
27. Obradovic A, Graves D, Korrer M, et al., 2022,
Immunostimulatory cancer-associated fibroblast 41. Bianchini G, De Angelis C, Licata L, et al., 2022, Treatment
subpopulations can predict immunotherapy response in landscape of triple-negative breast cancer-expanded options,
head and neck cancer. Clin Cancer Res., 28(10): 2094–2109. evolving needs. Nat Rev Clin Oncol., 19(2): 91–113.
28. Chowdhury N, Drake CG, 2020, Kidney cancer: An 42. Jiang YZ, Liu Y, Xiao Y, et al., 2021, Molecular subtyping and
overview of current therapeutic approaches. Urol Clin North genomic profiling expand precision medicine in refractory
Am., 47(4): 419–431. metastatic triple-negative breast cancer: The future trial. Cell
Res., 31(2): 178–186.
29. Daver N, Alotaibi AS, Bucklein V, et al., 2021, T-cell-
based immunotherapy of acute myeloid leukemia: Current 43. Carter JM, Polley MC, Leon-Ferre RA, et al., 2021,
concepts and future developments. Leukemia, 35(7): Characteristics and spatially defined immune (micro)
1843–1863. landscapes of early-stage PD-L1-positive triple-negative
breast cancer. Clin Cancer Res., 27(20): 5628–5637.
30. Lehmann BD, Jovanovic B, Chen X, et al., 2016, Refinement
of triple-negative breast cancer molecular subtypes: 44. Hammerl D, Martens JW, Timmermans M, et al., 2021,
Implications for neoadjuvant chemotherapy selection. PLoS Spatial immunophenotypes predict response to anti-PD1
One, 11(6): e0157368. treatment and capture distinct paths of T cell evasion in
triple negative breast cancer. Nat Commun., 12(1): 5668.
31. Rugo HS, Loi S, Adams S, et al., 2021, PD-L1
immunohistochemistry assay comparison in atezolizumab 45. Zhang Y, Chen H, Mo H, et al., 2021, Single-cell analyses
plus nab-paclitaxel-treated advanced triple-negative breast reveal key immune cell subsets associated with response
cancer. J Natl Cancer Inst., 113: 1733–1743. to PD-L1 blockade in triple-negative breast cancer. Cancer
Cell, 39(12): 1578–1593.e8.
32. Zhang R, Yang Y, Dong W, et al., 2022, D-mannose facilitates
immunotherapy and radiotherapy of triple-negative breast 46. Cruz C, Castroviejo-Bermejo M, Gutierrez-Enriquez S, et al.,
cancer via degradation of PD-L1. Proc Natl Acad Sci U S A., 208, RAD51 foci as a functional biomarker of homologous
119(8): e2114851119. recombination repair and PARP inhibitor resistance in
germline BRCA-mutated breast cancer. Ann Oncol., 29(5):
33. Kong T, Ahn R, Yang K, et al., 2020, CD44 promotes PD-L1 1203–1210.
expression and its tumor-intrinsic function in breast and
lung cancers. Cancer Res., 80(3): 444–457. 47. Liu L, Wang Y, Miao L, et al., 2018, Combination
immunotherapy of MUC1 mRNA nano-vaccine and
34. Qiu Y, Yang Y, Yang R, et al., 2021, Activated T cell-derived CTLA-4 blockade effectively inhibits growth of triple
exosomal PD-1 attenuates PD-L1-induced immune negative breast cancer. Mol Ther., 26(1): 45–55.
dysfunction in triple-negative breast cancer. Oncogene,
40(31): 4992–5001. 48. Miller RE, Leary A, Scott CL, et al., 2020, ESMO
recommendations on predictive biomarker testing for
35. Nair VS, Toor SM, Ali BR, et al., 2018, Dual inhibition of homologous recombination deficiency and PARP inhibitor
STAT1 and STAT3 activation downregulates expression benefit in ovarian cancer. Ann Oncol., 31(12): 1606–1622.
of PD-L1 in human breast cancer cells. Expert Opin Ther
Targets, 22(6): 547–557. 49. Zhang C, Chen L, Peng D, et al., 2020, METTL3 and
N6-methyladenosine promote homologous recombination-
36. Valencia-Hernandez I, Peregrina-Barreto H, Reyes-
Garcia CA, et al., 2021, Density map and fuzzy classification mediated repair of DSBs by modulating DNA-RNA hybrid
for breast density by using BI-RADS. Comput Methods accumulation. Mol Cell, 79(3): 425–442.e7.
Programs Biomed., 200: 105825. 50. De Angelis C, Nagi C, Hoyt CC, et al., 2020, Evaluation of
the predictive role of tumor immune infiltrate in patients
37. Lo CH, Chai XY, Ting SS, et al., 2020, Density of breast: with HER2-positive breast cancer treated with neoadjuvant
An independent risk factor for developing breast cancer, a anti-HER2 therapy without chemotherapy. Clin Cancer Res.,
prospective study at two premium breast centers. Cancer 26(3): 738–745.
Med., 9(9): 3244–3251.
51. Choueiri TK, Motzer RJ, Rini BI, et al., 2020, Updated
38. Brown KA, 2021, Metabolic pathways in obesity-related efficacy results from the JAVELIN renal 101 trial: First-
breast cancer. Nat Rev Endocrinol., 17(6): 350–363.
line avelumab plus axitinib versus sunitinib in patients
39. Maguire OA, Ackerman SE, Szwed SK, et al., 2021, Creatine- with advanced renal cell carcinoma. Ann Oncol., 31(8):
mediated crosstalk between adipocytes and cancer cells 1030–1039.

Volume 1 Issue 2 (2022) 9 https://doi.org/10.36922/td.v1i2.196